Premium
Pathogenic mutations in Parkinson disease
Author(s) -
Tan EngKing,
Skipper Lisa M.
Publication year - 2007
Publication title -
human mutation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.981
H-Index - 162
eISSN - 1098-1004
pISSN - 1059-7794
DOI - 10.1002/humu.20507
Subject(s) - parkin , biology , pink1 , genetics , lrrk2 , disease , penetrance , phenotype , parkinson's disease , mutation , neuroprotection , gene , proteasome , bioinformatics , neuroscience , pathology , medicine
Parkinson disease (PD; Parkinson's) is the second most common neurodegenerative disease, characterized by the progressive loss of dopamine neurons and the accumulation of Lewy bodies. Increasing evidence suggests that deficits in mitochondrial function, oxidative and nitrosative stress, the accumulation of aberrant or misfolded proteins, and ubiquitin‐proteasome system (UPS) dysfunction may represent the principal molecular pathways that commonly underlie the pathogenesis. The relative role of genetic and environmental factors has been the focus of research and debate. The recent discovery of a number of disease‐causing genes ( SNCA , Parkin/PARK2 , UCHL1 , PINK1 , DJ1/PARK7 , and LRRK2 ) in familial and sporadic forms of PD has provided considerable insights into the pathophysiology of this complex disorder. The frequency of these gene mutations may vary according to ethnicity and to the specific gene. A gene dosage effect is observed in some cases, and the phenotype of some of the mutation carriers closely resembles typical PD. Penetrance of some of the recurrent mutations is incomplete and may vary with age. Further research to unravel the etiopathology could identify biochemical or genetic markers for potential neuroprotective trials. Hum Mutat 28(7), 641–653, 2007. © 2007 Wiley‐Liss, Inc.